Effects of phosphodiesterase 10 inhibition on striatal cyclic amp and peripheral physiology in rats

Acta Neurobiologiae Experimentalis

Volumn 70, Issue 1, 2010, Pages 13-19

  Torremans, An ^a   Ahnaou, Abdellah ^a   van Hemelrijck, An ^a   Straetemans, Roel ^a   Geys, Helena ^a   Vanhoof, Greet ^a   Meert, Theo F ^a   Drinkenburg, Wilhelmus H ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

cAMP; MP10; Papaverine; PDE10

Indexed keywords

2 ((4 (1 METHYL 4 PYRIDIN 4 YL 1H PYRAZOL 3 YL)PHENOXY)METHYL)QUINOLINE; 2-((4-(1-METHYL-4-PYRIDIN-4-YL-1H-PYRAZOL-3-YL)PHENOXY)METHYL)QUINOLINE; CYCLIC AMP; PAPAVERINE; PHOSPHODIESTERASE INHIBITOR; PYRAZOLE DERIVATIVE; QUINOLINE DERIVATIVE;

ANIMAL; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE; BODY TEMPERATURE; CORPUS STRIATUM; DOSE RESPONSE; DRUG EFFECT; HEART RATE; MALE; METABOLISM; METHODOLOGY; MICRODIALYSIS; MOTOR ACTIVITY; PHYSIOLOGICAL PROCESS; RAT; SPRAGUE DAWLEY RAT; TELEMETRY; TIME;

ANIMALS; AREA UNDER CURVE; BLOOD PRESSURE; BODY TEMPERATURE; CORPUS STRIATUM; CYCLIC AMP; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART RATE; MALE; MICRODIALYSIS; MOTOR ACTIVITY; PAPAVERINE; PHOSPHODIESTERASE INHIBITORS; PHYSIOLOGICAL PHENOMENA; PYRAZOLES; QUINOLINES; RATS; RATS, SPRAGUE-DAWLEY; TELEMETRY; TIME FACTORS;

EID: 77952215394     PISSN: 00651400     EISSN: 00651400     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Essayan D (2001) Cyclic nucleotide phosphodiesterases. J Allergy Clin Immunol 108: 671-680.
2. Fujishige K, Kotera J, Michibata H, Yuasa K, Takebayashi S, Okumura K, Omori K (1999) Cloning and chracterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A). J Biol Chem 274: 18438-18445.
3. Guillin O, Abi-Dargham A, Laruelle M (2007) Neurobiology of dopamine in schizophrenia. Int Rev Neurobiol 78: 1-39.
4. Grauer SM, Pulito VL, Navarra RL, Kelly MP, Kelley C, Graf R, Langen B, Logue S, Brennan J, Jiang L, Charych E, Egerland U, Liu F, Marquis KL, Malamas M, Hage T, Comery TA, Brandon NJ (2009) Phosphdiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia. J Pharm Exp Ther 331: 574-590.
5. Hutson P, Suman-Chauhan N (1990) Activation of postsyn-aptic striatal dopamine receptors; monitored by efflux of cAMP in vivo. Neuropharmacology 29: 1011-1016
6. Iyo M, Bi Y, Hashimoto K, Inada T, Fukui S (1996) Prevention of metamphetamine-induced behavioural sensitisation in rats by a cyclic AMP phosphodiesterase inhibitor, rolipram. Eur J Pharmacol 312: 163-170.
7. Kapur S, Mamo D (2003) Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry 27: 1081-1090
8. Kehler J, Ritzén A, Greve DR (2007) The potential therapeutic use of phosphodiesterase 10 inhibitors. Expert Opin Ther Pat 17: 147-158.
9. αS within forebrain neurons causes deficits in sensorimotor gating because of PKA-dependent decreases in cAMP. Neuropsychopharmacology 32: 577-588.
10. Laitinen K, Salovaara K, Severgnini S, Laitinen J (1997) Regulation of cyclic GMP levels in the rat frontal cortex in vivo: effects of exogenous carbon monoxide and phos-phodiesterase inhibition. Brain Res 755: 272-278
11. Maxwell C, Kanes S, Abel T, Siegel S (2004) Phosphodiesterase inhibitors: a novel mechanism for receptor-independent antipsychotic medications. Neuroscience 129: 101-107.
12. Menniti F, Chappie T, Humphrey J, Schmidt C (2007) Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophrenia. Curr Opin Investig Drugs 8: 54-59.
13. Muly C (2002) Signal transduction abnormalities in schizophrenia: the cAMP system. Psychopharmacol Bull 36: 92-105.
14. rd ed.). Academic Press, San Diego, CA
15. Rodefer J, Murphy E, Baxter M (2005) PDE10A inhibition reverses subchronic PCP-induced deficits in attantional set-shifting in rats. Eur J Neurosci 21: 1070-1076
16. Santiago M, Westerink B (1990) Role of adenylate cyclase in the modulation of the release of dopamine: a microdialysis study in the striatum of the rat. J Neurochem 55: 169-174
17. Schmidt CJ, Chapin DS, Cianfrogna J, Corman ML, Hajos M, Harms JF, Hoffman WE, Lebel LA, McCarthy SA, Nelson FR, Proulx-LaFrance C, Majchrzak MJ, Ramirez AD, Schmidt K, Seymour PA, Siuciak JA, Tingley FD 3rd, Williams RD, Verhoest PR, Menniti FS (2008) Preclinical characterization of selective PDE10A inhibitors: A new therapeutic approach to the treatment of schizophrenia. J Pharmacol Exp Ther 325: 681-690.
18. Seeger TF, Bartlett B, Coskran TM, Culp JS, James LC, Krull DL, Lanfear J, Ryan AM, Schmidt CJ, Strick CA, Varghese AH, Williams RD, Wylie PG, Menniti FS (2003) Immunohistochemical localization of PDE10A in the rat brain. Brain Res 985: 113-126.
19. Siuciak JA, Chapin DS, Harms JF, Lebel LA, McCarthy SA, Chambers L, Shrikhande A, Wong S, Menniti FS, Schmidt CJ (2006) Inhibition of the striatum-enriched phosphodi-esterase PDE10A: A novel approach to the treatment of Psychosis. Neuropharmacology 51: 386-396
20. Wachtel H (1982) Characteristic behavioural alterations in rats induced by rolipram and other selective adenosinecyclic 3',5'-monophosphate phosphodiesterase inhibitors. Psychopharmacology 77: 309-316.
21. Wachtel H, Loschmann P, Schneider H, Rettig K (1987) Effects of forskolin on spontaneous behaviour, rectal temperature and brain cAMP levels of rats: interaction with rolipram. Neurosci Lett 76: 191-196.
22. Wadenberg MI, Hicks PB (1999) The conditioned avoidance response test re-evaluated: is it a sensitive test for the detection of potentially atypical antipsychotics? Neurosci Biobehav Rev 23: 851-858.